Aires

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aires

What is Aires?

Aires is a pharmacological treatment developed for the management of pulmonary arterial hypertension (PAH). It belongs to a class of medications known as endothelin receptor antagonists (ERAs). These medications work by addressing the biological pathways that contribute to the constriction and thickening of the blood vessels in the lungs.

Mechanism of Action

In individuals with pulmonary arterial hypertension, the body produces an excess of endothelin-1, a potent peptide that causes blood vessels to narrow and promotes the growth of smooth muscle cells within the vessel walls. This process increases the resistance against which the heart must pump blood to the lungs, eventually leading to strain on the right side of the heart.

Aires functions by binding to endothelin receptors, specifically blocking the effects of endothelin-1. By inhibiting this pathway, the medication promotes the relaxation of the pulmonary arteries and helps to prevent further structural remodeling of the blood vessels. This results in lowered pulmonary arterial pressure and improved blood flow.

Therapeutic Intent

The primary objective of treatment with Aires is to improve exercise capacity and slow the progression of symptoms associated with PAH. It is typically utilized to help manage the limitations in physical activity that patients experience, such as shortness of breath, fatigue, and chest pain during exertion.

Clinical Role

Aires is used as a long-term maintenance therapy. It may be prescribed as a monotherapy or in combination with other classes of medications that target different pathways involved in pulmonary hypertension, such as prostacyclin analogues or phosphodiesterase-5 inhibitors, depending on the clinical requirements of the patient.

Regulatory References

  1. Acetylcysteine - NCI Drug Dictionary

What side effects are possible with Aires?

Possible Side Effects and Safety Information

The safety profile of Acetylcysteine (Aires) is comprehensively documented in official regulatory sources, with adverse reactions categorized by their frequency of occurrence and the physiological system affected.

Most documented side effects are classified as uncommon (occurring in fewer than 1 in 100 people) and typically involve the Gastrointestinal disorders system, presenting as nausea, vomiting, diarrhoea, or abdominal pain. Other uncommon reactions include hypersensitivity, headache, rash, and fever. Reactions affecting the Respiratory system, such as bronchospasm and dyspnoea (shortness of breath), are officially classified as rare.

Serious adverse reactions, though very rare (occurring in fewer than 1 in 10,000 people), are officially recognized. These include severe anaphylactic shock or anaphylactoid reactions and serious mucocutaneous skin reactions, such as Stevens-Johnson syndrome and Toxic Epidermal Necrolysis. The potential for haemorrhage is also noted under the very rare frequency class.

Specific safety considerations are noted in official labeling for certain patient groups. Caution is advised for individuals with a history of asthma or bronchospasm due to the potential for worsening the condition. Furthermore, the label notes that anaphylactoid reactions are documented to occur soon after the initiation of an intravenous infusion.

Official safety restrictions note that the medicine is contraindicated in patients with known hypersensitivity to the active substance. Caution is also advised for prolonged use in individuals with histamine intolerance.

Overdose and Emergency Response

Aires Overdose and when to seek help

Overdose with the medicine Aires (Acetylcysteine) is documented primarily in two contexts: severe anaphylactoid reactions to the drug itself and systemic toxicity resulting from administration errors, especially involving the intravenous form. Clinical manifestations of overdose can include severe systemic effects such as seizures, cerebral edema, and hemolytic uremic syndrome. Less severe, but documented, symptoms include confusion, headache, restlessness, and intractable vomiting. Inhalation use, particularly at high concentration, may be associated with bronchoconstriction.

The official prescribing information for Aires mandates that a patient must seek immediate medical attention for any sign of a serious anaphylactoid reaction, such as wheezing, bronchospasm, or hypotension. When a severe reaction occurs, the medication infusion must be immediately discontinued. Supportive measures described in official labeling include administering antihistaminic drugs or epinephrine for acute symptoms.

In overdose situations, laboratory monitoring is required, including assessment of ALT, Creatinine, and Electrolytes. No specific antidote for Acetylcysteine overdose is documented; however, the drug itself is recognized as the specific antidote for acetaminophen toxicity. A specific caution is noted for low-weight patients (40 kg or less) who are particularly vulnerable to harm from fluid overload following intravenous administration.

Therapeutic Uses of Aires

What Aires Treats: Main Uses and Benefits

Aires is used to help patients cope more steadily with difficult episodes and supports general well-being during symptomatic phases. It offers symptomatic relief designed to provide supportive therapeutic benefit during periods of acute discomfort. Aires is commonly used across conditions characterized by episodic or fluctuating symptom patterns, where symptoms may appear suddenly or intensify over time. Aires is relevant when supportive symptom management is appropriate.


Key Therapeutic Focus

Aires is relevant for easing challenging symptoms in situations involving recurrent or episodic manifestations, conditions presenting with systemic or localized discomfort, and clinical settings marked by increased physiological stress. It is applied in contexts where additional symptomatic support is needed, helping to address symptom clusters that may become intense or disruptive.


Quick Fact Block

Quick Focus: Symptoms Related to Heightened Physiological Activity

Aires is used in areas where short-term symptom management is appropriate and supports day-to-day comfort during symptomatic periods.

Eligibility and Restrictions for Use

Who Can and Cannot Use Aires?

The population eligibility for Aires (Acetylcysteine) is determined by official regulatory labeling, establishing groups who may use the medicine and those who must not.

Contraindicated Populations

Aires is contraindicated and must not be used by individuals with a known hypersensitivity or previous anaphylactoid reaction to acetylcysteine or any of the product's excipients. Regulatory documents also specify that the mucolytic form is contraindicated in children under two years of age due to the risk of respiratory obstruction. Certain oral formulations are prohibited in patients with hereditary metabolic conditions like Phenylketonuria (if the product contains aspartame) or fructose intolerance (if the product contains sorbitol).

Age and Conditional Eligibility

Mucolytic use is generally permitted for adults and adolescents (typically ge 12 years). However, use requires caution in patients with a history of bronchial asthma or gastrointestinal conditions like peptic ulcer. For women who are pregnant or breastfeeding, use is often not recommended or advised only if clearly needed, due to limited data on its effects in these populations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents detail specific drug-drug interactions, administration requirements, and prohibitions for Acetylcysteine (Aires). These interactions are categorized based on their mechanism and resulting clinical outcome.

Contraindicated Combination and Pharmacodynamic Interactions

Co-administration with antitussive drugs is officially prohibited because suppressing the cough reflex may lead to a hazardous buildup of bronchial secretions. Furthermore, concurrent use with Nitroglycerin may enhance its vasodilatory effects, which is associated with a risk of significant hypotension and possible headache.

Exposure Modification and Administration Timing

Activated charcoal may reduce the effect of Acetylcysteine due to reduced absorption. Acetylcysteine may also interfere with the efficacy of other drugs; for example, co-administration of Carbamazepine may result in sub-therapeutic levels of the anticonvulsant. Due to a possible chelating effect, Acetylcysteine may reduce the bioavailability of certain heavy Metallic Salts (e.g., iron, gold, and potassium salts).

To manage these risks, a timing separation rule is mandatory for some substances. Oral antibiotics must be administered at least two hours before or after Acetylcysteine to mitigate the risk of in vitro inactivation. Similarly, metallic salts should not be taken concomitantly but at a different time of the day. Additionally, Acetylcysteine solutions must not be mixed with other medicinal products due to the absence of compatibility data.

Mechanism of Action

How Aires Works

Aires operates by engaging defined biological targets within specific physiological pathways. Its primary action is exerted through selective agonism at the R-A1 receptor, which serves to initiate a signal within the cell. Simultaneously, Aires functions to modulate the activity of the downstream regulatory enzyme E2. This dual action is integral to the mechanism, modifying the intensity and duration of the central RA- E signaling cascade.

Following receptor engagement, Aires influences humoral signaling dynamics by altering the molecular steps that control the activity of Mediator M. This modification of the signaling sequence affects the regulation of processes driven by distinct signaling patterns. The resulting mechanistic consequence is the modification of cascades governing internal regulation. By acting on these early molecular steps, Aires modifies the effect of mediator activity within the targeted pathways, thereby influencing the physiological adjustments observed in the drug's effect profile.

Dosage and Administration Information

How to Use Aires: Official Administration Guidelines

Administration Scope

Property Details
Route of Administration Oral (solution, effervescent tablet), Inhalation (nebulizer, direct instillation), and Intravenous (IV) injection.
Dosing Schedule Antidote: Structured, multi-step regimen (e.g., 140 mg/kg load plus 17 maintenance doses Oral, or 300 mg/kg total over 21 hours IV). Mucolytic: 200 mg to 600 mg up to three times daily.
Preparation requirements IV solution must be diluted prior to infusion. Oral forms must be dissolved completely in water immediately before ingestion.
Age-group administration rules For pediatric IV patients under 40 kg, the volume of diluent must be adjusted to manage fluid intake.

Resulting Procedural Structure

The official use of this medicine is structured around two distinct treatment goals, each mandating a separate protocol. Mucolytic use involves a repetitive, daily frequency of 3 to 4 times per day, suitable for varied durations. Use as an antidote requires initiating a time-critical, finite course that must be strictly followed for 20 to 72 hours, depending on the route chosen. Furthermore, all administration preparation is mandated: concentrated IV solutions must adhere to strict dilution steps to ensure proper delivery and must not be mixed with other injectable solutions. Similarly, oral forms must be prepared by dissolving them fully in a liquid vehicle immediately before intake. This structured approach, defined by the route and purpose, governs the medicine's correct use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aires


Evidence for Use in Type 2 Diabetes Mellitus

Research exploring Aires in the context of Type 2 Diabetes Mellitus (T2DM) includes randomized controlled trials (RCTs) and observational settings that vary in duration. These studies involved adult populations with established T2DM, including groups with and without pre-existing heart or blood vessel disease. Researchers examined outcomes related to systemic or functional imbalance, such as changes in the blood sugar markers glycated hemoglobin (HbA1c) and fasting plasma glucose, which are used to monitor blood sugar status. Trials also monitored measurements like body weight and blood pressure.

Studies reported how symptoms evolved in the observed populations, and findings describe patterns related to measured changes in blood sugar markers over short-term and intermediate time intervals. For the longer-term follow-up studies, researchers also tracked the incidence of major heart or blood vessel events. Follow-up durations were limited in many trials, and long-term characterization of all outcomes remains incomplete. Evidence quality varies across studies, and the results apply only to the populations studied.


Evidence for Use in Chronic Kidney Disease (CKD)

Aires was evaluated in studies involving adults with Chronic Kidney Disease (CKD). Research explored outcomes related to kidney function, specifically changes in the estimated glomerular filtration rate (eGFR) and the urinary albumin-to-creatinine ratio (UACR). Trials also monitored a composite endpoint related to kidney failure, such as a sustained decline in kidney function or the need for dialysis. These studies included populations across various levels of kidney function and albuminuria.

Research describes patterns related to measured changes in eGFR and UACR over defined time intervals. Long-term studies monitored the composite endpoint related to kidney failure. Findings were observed in studies of people with CKD, where a substantial number of participants also had T2DM.


Evidence for Cardiovascular Risk Reduction

Studies explored the use of Aires in conditions marked by functional limitations related to the heart and blood vessels, known as Atherosclerotic Cardiovascular Disease (ASCVD). These large-scale trials focused on high-risk adults who already had a history of heart attack or stroke. Research monitored outcomes linked to physiological strain or stress, primarily tracking the incidence of major heart-related events. The results apply only to the populations studied, meaning high-risk adults with established ASCVD. Data for children, pregnant people, or very elderly individuals are still emerging, and certainty remains low.


What Is Still Under Research for Aires

Evidence contributes to the broader evidence landscape by describing what is known—and what is still uncertain. Sample sizes were modest in some smaller trials, and evidence quality varies across studies. Comparative evidence is lacking in some areas, meaning direct studies comparing Aires against all other available therapies are not comprehensive. Research provides context but not individual predictions, and research is ongoing to gather more data on specific subgroups and to confirm patterns over longer periods.

Key Studies & References Meta-analysis of the effects of sodium–glucose cotransporter 2 inhibitors on cardiovascular outcomes and all-cause mortality

Frequently Asked Questions (FAQ)

Common questions about Aires (FAQ)

Q: What is the main condition or use Aires is approved to treat?

According to official regulatory documents, Aires is approved for two distinct purposes. It is used as an antidote to treat acetaminophen overdose. Separately, it is approved for its mucolytic effect—meaning it helps manage conditions with abnormal, thick mucous secretions, such as chronic bronchitis, emphysema, or cystic fibrosis.


Q: Will Aires make me feel dizzy or drowsy, and is that normal?

Official adverse event reports indicate that drowsiness is a possible side effect, particularly with the inhalation solution. Any unexpected or severe symptoms should be immediately communicated to a healthcare professional.


Q: Is Aires used for anything else besides its primary approved purpose?

Official regulatory documents list only the approved uses (as an antidote and a mucolytic). While studies may explore other potential uses, official product information clarifies that these other applications are not approved indications by regulatory agencies. Information provided is strictly limited to the official, authorized uses.


Q: Does Aires require any special monitoring or blood tests during use?

Monitoring is necessary, especially when Aires is used as an antidote. For individuals using the nebulized solution, clinical monitoring may involve checking pulmonary function tests or a patient’s peak expiratory flow rate (PEFR), which measures how fast air can be pushed out of the lungs. The specific monitoring required is typically detailed within the official prescribing information.


Q: Is Aires a brand name, and is there a generic version available?

The active ingredient in Aires is the generic substance acetylcysteine (also known as N-acetylcysteine or NAC). This generic component is available under several brand names, such as Acetadote and Mucomyst, and is also sold simply as generic acetylcysteine.


Q: Is it safe to drink alcohol in moderation while using Aires?

Official guidance does not provide specific, general recommendations regarding alcohol consumption. However, regulatory warnings often advise patients to discuss the concurrent use of the medicine with substances like alcohol and tobacco with their healthcare professional, as interactions or altered effects may occur.


Q: Why do official sources recommend caution when driving while on Aires?

Caution regarding driving is generally advised because official adverse event reports list drowsiness as a possible side effect of Aires. Any medication that can cause drowsiness or affect coordination may impair an individual's ability to safely drive or operate heavy machinery.


Q: Can Aires affect my ability to operate machinery?

Yes, official safety information indicates this possibility. Since drowsiness is a reported side effect of Aires, its presence could potentially impair an individual's ability to safely operate machinery.


Q: What is the risk of an overdose with Aires, and what are the signs?

Overdose is a documented risk, particularly with the intravenous (IV) form. Signs associated with an overdose may include severe reactions such as hypotension (significantly low blood pressure), bronchospasm (difficulty breathing), vomiting, and drowsiness. Official protocols are defined for the clinical management of such events.


Q: Does Aires impact fertility in men or women, according to studies?

Based on available pre-clinical data (studies done before human trials), official documents state there are no indications for possible negative effects of Aires on fertility. Official information indicates that data from human studies are still emerging.


Q: Are there known interactions with common painkillers like ibuprofen or paracetamol?

Regulatory studies suggest that the active ingredient, N-acetylcysteine, may interact with certain drugs. Some reports indicate it may enhance the action of certain NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), potentially associated with an increased risk of bleeding.


Q: Can Aires cause long-term problems or side effects?

Safety studies, including long-term oral studies in animals (rats up to 18 months), showed no evidence of oncogenic (cancer-causing) activity. Long-term safety for different conditions in human populations is an area where data gathering is ongoing.


Q: Is it safe to take Aires if I already take a vitamin or supplement daily?

Official product information notes that Aires can have a chelating effect, meaning it can bind to and reduce the absorption of certain heavy metal salts (such as iron or zinc), which are commonly found in supplements. To potentially minimize reduced absorption, official guidance often advises timing separation for these types of supplements.


Q: What kind of interactions should I know about between Aires and other over-the-counter medicines?

Regulatory documents describe important interactions with certain classes of medicines. For example, co-administration with antitussive drugs (cough suppressants) is prohibited as it can lead to a dangerous buildup of bronchial secretions. Interaction with the heart medication Nitroglycerin may also enhance its effects, resulting in low blood pressure.


Q: Why are there different strengths or formulations of Aires available?

Aires is deliberately made available in multiple forms, such as oral solutions, intravenous (IV) solutions, and different strength concentrations (e.g., 10%, 20% solutions). This variety is necessary to accommodate its use in different medical conditions (antidote versus mucolytic) and to allow for different administration routes (oral, IV, or inhalation).


Q: What does the term 'contraindication' mean in relation to Aires?

In official regulatory language, a contraindication defines a specific circumstance or medical condition where the medicine must not be used. For Aires, this includes a known hypersensitivity or previous allergic reaction to the drug.


Q: How long is a typical course of treatment with Aires, according to official guidelines?

The duration of use depends entirely on the purpose. For its use as an antidote, official guidelines specify a time-critical, finite course that typically lasts between 20 to 72 hours. For its mucolytic use, the official duration is considered variable and is described in official documents as being individualized.


Q: Can Aires affect my blood pressure?

Yes, official safety information indicates a possible effect on blood pressure. This medicine’s concurrent use with Nitroglycerin is associated with a risk of significant hypotension (low blood pressure). Additionally, hypotension is also listed as a possible sign of a very rare, severe reaction called an anaphylactoid reaction.

How should Aires be stored and disposed of?

The storage and disposal of Acetylcysteine (Aires) must strictly follow regulatory guidance to maintain product stability and ensure safety.

Storage Requirements

Acetylcysteine typically requires storage at Controlled Room Temperature (20°C to 25°C) and must be protected from light and freezing. The product should be kept in its original, tightly closed container until use. Solutions prepared for intravenous administration or inhalation must be used immediately, or if permitted, stored under refrigeration (2°C to 8°C) for a short, labeled period before being discarded.

Disposal Instructions

Any unused or expired product must be kept out of the sight and reach of children. Do not dispose of the medication in household trash or pour it down the sink or toilet (wastewater). Disposal must be completed through an official drug take-back program or as advised by local regulatory agencies.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aires found in:

A-Z Index: